Kane, J, Honigfeld, G, Singer, J, Meitzer, H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry
1988; 45: 789–96.
Harvey, PD, Keefe, RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry
2001; 158: 176–84.
Geddes, J, Freemantle, N, Harrison, P, Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ
2000; 321: 1371–6.
Leucht, S, Wahlbeck, K, Hamann, J, Kissling, W. New generation antipsychotics vs low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet
2003; 36: 1581–9.
Davis, JM, Chen, N, Glick, ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry
2003; 60: 553–64.
Heres, S, Davis, J, Maino, K, Jetzinger, E, Kissling, W, Leucht, S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry
2006; 163: 185–94.
Tunis, SR, Stryer, DB, Clancy, CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA
2003; 290: 1624–32.
Lieberman, JA, Stroup, S, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, Keefe, RSE, Davis, SM, Davis, CE, Lebowitz, BD, Severe, J, Hsiao JK, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med
2005; 353: 1209–23.
Keefe, RS, Bilder, RM, Davis, SM, Harvey, PD, Palmer, BW, Gold, JM, Meltzer, HY, Green, MF, Capuano, G, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, Davis, CE, Hsiao, JK, Lieberman, JA, for the CATIE Investigators and the Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry
2007; 64: 633–47.
McEvoy, JP, Lieberman, JA, Stroup, TS, Davis, SM, Meltzer, HY, Rosenheck, RA, Swartz, MS, Perkins, DO, Keefe, RSE, Davis, CE, Severe, J, Hsiao JK, for the CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry
2006; 163: 600–10.
Jones, PB, Barnes, TR, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, Murray, RM, Markwick, A, Lewis, SW. Randomized controlled trial of effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry
2006; 63: 1079–87.
Lewis, SW, Barnes, TRE, Davies, L, Murray, RM, Dunn, G, Hayhurst, KP, Markwick, A, Lloyd, H, Jones, PB. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull
2006; 32: 715–23.
Essock, SM, Covell, NH, Davis, SM, Stroup, TS, Rosenheck, RA, Lieberman, JA. Effectiveness of switching antipsychotic medications. Am J Psychiatry
2006; 163: 2090–5.
Soares, BG, Fenton, F, Chue, P. Sulpiride for schizophrenia
Cochrane Library, issue 3. , 2002.
Correll, CU, Leucht, S, Kane, JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry
2004; 161: 414–25.
Rosenheck, R, Perlick, D, Bingham, S, Liu-Mares, W, Collins, J, Warren, S, Leslie, D, Allan, E, Campbell, EC, Caroff, S, Corwin, J, Davis, L, Douyon, R, Dunn, L, Evans, D, Frecska, E, Grabowski, J, Graeber, D, Herz, L, Kwon, K, Lawson, W, Mena, F, Sheikh, J, Smelson, D, Smith-Gamble V, for the Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. A randomised controlled trial. JAMA
2003; 29: 2693–702.
Rosenheck, RA, Leslie, D, Sindelar, J, Miller, EA, Lin, H, Stroup, TS, McEvoy, J, Davis, SM, Keefe, RSE, Swartz, MS, Perkins, DO, Hsiao, JK, Lieberman J, for the CATIE Study Investigators. Cost-effectiveness of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry
2006; 163: 2080–9.
Davies, LM, Lewis, S, Jones, PB, Barnes, TRE, Gaughran, F, Hayhurst, K, Markwick, A, Lloyd H on behalf of the CUtLASS team. Cost-effectiveness of first-v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry
2007; 191: 14–22.
Lieberman, JA, Tollefson, G, Tohen, M, Green, AI, Gur, RE, Kahn, R, McEvoy, J, Perkins, D, Sharma, T, Zipursky, R, Wei, H, Hamer RM, and the HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized double-blind trial of olanzapine vs haloperidol. Am J Psychiatry
2003; 160: 1396–404.
Schooler, N, Robinowitz, J, Davidson, M, Emsley, R, Harvey, PD, Kopala, L, McGorry, PD, Van Hove, I, Eerdekens, M, Swyzen, W, De Smedt, G. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry
2005; 162: 947–53.